Shares of Seattle Genetics, Inc. (NASDAQ:

) are higher on the session by 1.34%, trading at $18.91. Overall put volume is now running at 3.04x the daily average, with 52% of all puts traded being purchases on the offer. 2,548 contracts have traded on the session so far. Seattle Genetics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.